ASH 2023 Leukemia/MDS/Myelofibrosis Highlights – TRANSFORM-1, MANIFEST-2, SAVE, AUGMENT-101

In discussion with Dr. Uma Borate from the Ohio State University Comprehensive Cancer Center, The James, covering the leukemia, myelofibrosis and myelodysplastic syndrome key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Borate:

- TRANSFORM-1: Ph III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, International, Study of Navitoclax in Combination with Ruxolitinib vs Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis

- MANIFEST-2: Ph III, Randomized, Double-Blind Study, Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis

- SAVE: Phase I/II, Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in AML

- AUGMENT-101: Ph I/II, Revumenib Monotherapy in Patients with R/R KMT2Ar Acute Leukemias: Efficacy and Safety Results

#ASH #Leukemia #MDS #Myelofibrosis #Blood #Cancer #2023 #oncology #oncbrothers

Website: http://www.oncbrothers.com/

Twitter:   / oncbrothers  

Contact us at [email protected]